A Phase 2 interventional study of Pemigatinib in Cholangiocarcinoma, sponsored by Incyte Corporation. Completed at 120 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-14.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing pemigatinib in Cholangiocarcinoma — 6 open to participants now, 6 under way, none of them phase 3. pemigatinib · Cholangiocarcinoma.
Among the 13 studies testing pemigatinib in Cholangiocarcinoma, this one is the 3rd largest by enrollment, is the only one that started in 2017, is one of 8 in phase 2, and was the 2nd registered.
825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.
Browse Cholangiocarcinoma studies →6 of the 13 studies testing pemigatinib in Cholangiocarcinoma are open now, in 1 country. Recruiting first, the newest first:
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
Mehmet Akce · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Incyte Corporation
Ages 18+
By country, each count listing its studies:
pemigatinib: first FDA approval 2020 (PEMAZYRE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 1
First in 2015; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 147 is above the median of 50 across 624 interventional studies indexed under Cholangiocarcinoma.
Median enrollment 34 across the 13 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 13 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
Incyte Corporation has 5 studies filed under Cholangiocarcinoma — fewer than ten, so there is no comparison to draw.
1 of the studies testing pemigatinib in Cholangiocarcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06728410Mehmet AkceA Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing pemigatinib in Cholangiocarcinoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is evaluate the efficacy of pemigatinib in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pemigatinib in subjects with FGFR2 translocation with a documented fusion partner in central laboratory report
Drug: Pemigatinib
Pemigatinibin subjects with other FGF/FGFR alterations
Drug: Pemigatinib
Pemigatinib in subjects negative for FGF/FGFR alteration
Drug: Pemigatinib
Pemigatinibonce a day by mouth for 2 consecutive weeks and 1 week off therapy
Also known as: INCB054828
Objective Response Rate (ORR) in Participants With FGFR2 Rearrangements or Fusions
ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) at any post-Baseline visit prior to first progressive disease (PD), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1). CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.
Time frame: up to 1527 days
ORR in Participants FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions
ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.
Time frame: up to 424 days
ORR in All Participants With FGF/FGFR Alterations
ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.
Time frame: up to 1527 days
ORR in Participants Negative for FGF/FGFR Alterations
ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.
Time frame: up to 143 days
Progression-free Survival (PFS)
PFS was defined as the length of time from the first dose of study drug (Day 1) to the earlier of death or disease progression by RECIST v1.1, as assessed by the independent centralized radiological review committee.
Time frame: up to 50.17 months
Duration of Response (DOR)
DOR was defined as the time from the first overall response contributing to an objective response (CR or PR) as assessed by an independent centralized radiological review committee to the earlier of death or first overall response of PD occurring after the first overall response contributing to the objective response. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.
Time frame: up to 47.11 months
Disease Control Rate (DCR)
DCR was defined as the proportion of participants with an overall response of CR, PR, or stable disease (SD), per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.
Time frame: up to 1527 days
Overall Survival
Overall survival was defined as the length of time from the first dose of study drug (Day 1) until the date of death due to any cause.
Time frame: up to 51.32 months
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. Abnormal laboratory values or test results occurring after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). A TEAE was defined as any adverse event either reported for the first time or the worsening of a pre-existing event after the first dose of study drug and within 30 days of the last dose of study drug.
Time frame: up to 1584 days
First-order Absorption Rate Constant (ka) of Pemigatinib
First-order absorption rate constant is defined as the rate at which a drug enters into the system.
Time frame: Predose; 1-2 hours post-dose; 4-12 hours post-dose
CL/F of Pemigatinib
CL/F is defined as apparent oral clearance.
Time frame: Predose; 1-2 hours post-dose; 4-12 hours post-dose
Vc/F of Pemigatinib
Vc/F is defined as the apparent volume of distribution for the central compartment of pemigatinib.
Time frame: Predose; 1-2 hours post-dose; 4-12 hours post-dose
Vp/F of Pemigatinib
Vp/F is defined as the apparent volume of distribution for the tissue (peripheral) compartment.
Time frame: Predose; 1-2 hours post-dose; 4-12 hours post-dose
| Milestone | Cohort A: FGFR2 Rearrangements or Fusions | Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions | Cohort C: Negative for FGF/FGFR Alterations | Other |
|---|---|---|---|---|
| Started | 108 | 20 | 17 | 2 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 108 | 20 | 17 | 2 |
| Withdrew: Progressive disease | 4 | 0 | 1 | 0 |
| Withdrew: Death | 73 | 18 | 15 | 2 |
| Withdrew: Lost to follow-up | 3 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 19 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 2 | 1 | 0 |
| Withdrew: Rolled over to another study | 1 | 0 | 0 | 0 |
ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) at any post-Baseline visit prior to first progressive disease (PD), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1). CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.
| percentage of participants | Cohort A: FGFR2 Rearrangements or Fusions | Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions | Cohort C: Negative for FGF/FGFR Alterations | Other |
|---|---|---|---|---|
| Objective Response Rate (ORR) in Participants With FGFR2 Rearrangements or Fusions | 37.0 (27.94 to 46.86) | — | — | — |
ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.
| percentage of participants | Cohort A: FGFR2 Rearrangements or Fusions | Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions | Cohort C: Negative for FGF/FGFR Alterations | Other |
|---|---|---|---|---|
| ORR in Participants FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions | — | 0.0 (0.0 to 16.84) | — | — |
ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.
| percentage of participants | Cohort A: FGFR2 Rearrangements or Fusions | Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions | Cohort C: Negative for FGF/FGFR Alterations | Other | Cohort A + Cohort B |
|---|---|---|---|---|---|
| ORR in All Participants With FGF/FGFR Alterations | — | — | — | — | 31.3 (23.35 to 40.04) |
ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. ORR was based on central genomics laboratory results. Response was based on review of scans by an independent centralized radiological review committee.
| percentage of participants | Cohort A: FGFR2 Rearrangements or Fusions | Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions | Cohort C: Negative for FGF/FGFR Alterations | Other |
|---|---|---|---|---|
| ORR in Participants Negative for FGF/FGFR Alterations | — | — | 0.0 (0.0 to 19.51) | — |
PFS was defined as the length of time from the first dose of study drug (Day 1) to the earlier of death or disease progression by RECIST v1.1, as assessed by the independent centralized radiological review committee.
| months | Cohort A: FGFR2 Rearrangements or Fusions | Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions | Cohort C: Negative for FGF/FGFR Alterations | Other |
|---|---|---|---|---|
| Progression-free Survival (PFS) | 7.03 (6.08 to 10.48) | 2.10 (1.18 to 4.86) | 1.51 (1.38 to 1.84) | — |
DOR was defined as the time from the first overall response contributing to an objective response (CR or PR) as assessed by an independent centralized radiological review committee to the earlier of death or first overall response of PD occurring after the first overall response contributing to the objective response. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.
| months | Cohort A: FGFR2 Rearrangements or Fusions | Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions | Cohort C: Negative for FGF/FGFR Alterations | Other |
|---|---|---|---|---|
| Duration of Response (DOR) | 9.13 (6.01 to 14.49) | — | — | — |
DCR was defined as the proportion of participants with an overall response of CR, PR, or stable disease (SD), per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.
| percentage of participants | Cohort A: FGFR2 Rearrangements or Fusions | Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions | Cohort C: Negative for FGF/FGFR Alterations | Other |
|---|---|---|---|---|
| Disease Control Rate (DCR) | 82.4 (73.9 to 89.1) | 40.0 (19.1 to 63.9) | 17.6 (3.8 to 43.4) | — |
Overall survival was defined as the length of time from the first dose of study drug (Day 1) until the date of death due to any cause.
| months | Cohort A: FGFR2 Rearrangements or Fusions | Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions | Cohort C: Negative for FGF/FGFR Alterations | Other |
|---|---|---|---|---|
| Overall Survival | 17.48 (14.36 to 22.93) | 6.70 (2.10 to 10.55) | 3.98 (1.97 to 4.60) | — |
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. Abnormal laboratory values or test results occurring after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). A TEAE was defined as any adverse event either reported for the first time or the worsening of a pre-existing event after the first dose of study drug and within 30 days of the last dose of study drug.
| Participants | Cohort A: FGFR2 Rearrangements or Fusions | Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions | Cohort C: Negative for FGF/FGFR Alterations | Other |
|---|---|---|---|---|
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 108 | 20 | 17 | 2 |
First-order absorption rate constant is defined as the rate at which a drug enters into the system.
| 1/hour | All Cohorts |
|---|---|
| First-order Absorption Rate Constant (ka) of Pemigatinib | 1.29 ± 0.827 |
CL/F is defined as apparent oral clearance.
| Liters/hour | All Cohorts |
|---|---|
| CL/F of Pemigatinib | 12.2 ± 5.28 |
Vc/F is defined as the apparent volume of distribution for the central compartment of pemigatinib.
| Liters | All Cohorts |
|---|---|
| Vc/F of Pemigatinib | 144 ± 55.7 |
Vp/F is defined as the apparent volume of distribution for the tissue (peripheral) compartment.
| Liters | All Cohorts |
|---|---|
| Vp/F of Pemigatinib | 85.6 ± 30.5 |
Collected over up to 1584 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A: FGFR2 Rearrangements or Fusions | 76/108 (70.4%) | 46/108 (42.6%) | 108/108 (100%) |
| Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions | 18/20 (90%) | 10/20 (50%) | 20/20 (100%) |
| Cohort C: Negative for FGF/FGFR Alterations | 15/17 (88.2%) | 12/17 (70.6%) | 17/17 (100%) |
| Other | 2/2 (100%) | 0/2 (0%) | 2/2 (100%) |
| Total | 111/147 (75.5%) | 68/147 (46.3%) | 147/147 (100%) |
| Event | Cohort A: FGFR2 Rearrangements or Fusions | Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions | Cohort C: Negative for FGF/FGFR Alterations | Other | Total |
|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 4/108 | 1/20 | 2/17 | 0/2 | 7/147 |
| Back painMusculoskeletal and connective tissue disorders | 0/108 | 0/20 | 2/17 | 0/2 | 2/147 |
| HyponatraemiaMetabolism and nutrition disorders | 1/108 | 2/20 | 0/17 | 0/2 | 3/147 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/108 | 2/20 | 1/17 | 0/2 | 5/147 |
| Acute kidney injuryRenal and urinary disorders | 2/108 | 0/20 | 1/17 | 0/2 | 3/147 |
| AnaemiaBlood and lymphatic system disorders | 1/108 | 0/20 | 1/17 | 0/2 | 2/147 |
| Anaphylactic reactionImmune system disorders | 0/108 | 0/20 | 1/17 | 0/2 | 1/147 |
| BilomaHepatobiliary disorders | 0/108 | 0/20 | 1/17 | 0/2 | 1/147 |
| Blood creatinine increasedInvestigations | 1/108 | 0/20 | 1/17 | 0/2 | 2/147 |
| CholangitisHepatobiliary disorders | 5/108 | 0/20 | 1/17 | 0/2 | 6/147 |
| Event | Cohort A: FGFR2 Rearrangements or Fusions | Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions | Cohort C: Negative for FGF/FGFR Alterations | Other | Total |
|---|---|---|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 64/108 | 4/20 | 3/17 | 2/2 | 73/147 |
| Dry mouthGastrointestinal disorders | 42/108 | 5/20 | 1/17 | 2/2 | 50/147 |
| Dry skinSkin and subcutaneous tissue disorders | 30/108 | 0/20 | 0/17 | 2/2 | 32/147 |
| DysgeusiaNervous system disorders | 45/108 | 3/20 | 3/17 | 2/2 | 53/147 |
| HyperphosphataemiaMetabolism and nutrition disorders | 60/108 | 13/20 | 12/17 | 1/2 | 86/147 |
| DiarrhoeaGastrointestinal disorders | 58/108 | 5/20 | 6/17 | 1/2 | 70/147 |
| FatigueGeneral disorders | 50/108 | 5/20 | 9/17 | 0/2 | 64/147 |
| Abdominal painGastrointestinal disorders | 22/108 | 3/20 | 3/17 | 1/2 | 29/147 |
| Activated partial thromboplastin time prolongedInvestigations | 3/108 | 0/20 | 0/17 | 1/2 | 4/147 |
| ConstipationGastrointestinal disorders | 46/108 | 5/20 | 2/17 | 1/2 | 54/147 |
| Age, Continuous(years) | Cohort A: FGFR2 Rearrangements or Fusions | Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions | Cohort C: Negative for FGF/FGFR Alterations | Other | Total |
|---|---|---|---|---|---|
| Mean | 55.2 ± 12.00 | 61.9 ± 10.99 | 65.6 ± 7.12 | 41.0 ± 14.14 | 57.1 ± 12.08 |
| Sex: Female, Male(Participants) | Cohort A: FGFR2 Rearrangements or Fusions | Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions | Cohort C: Negative for FGF/FGFR Alterations | Other | Total |
|---|---|---|---|---|---|
| Female | 66 | 11 | 7 | 1 | 85 |
| Male | 42 | 9 | 10 | 1 | 62 |
| Race/Ethnicity, Customized(Participants) | Cohort A: FGFR2 Rearrangements or Fusions | Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions | Cohort C: Negative for FGF/FGFR Alterations | Other | Total |
|---|---|---|---|---|---|
| White | 79 | 9 | 14 | 2 | 104 |
| Black or African American | 7 | 0 | 1 | 0 | 8 |
| Asian | 12 | 11 | 0 | 0 | 23 |
| American-Indian/Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Captured as "Other" | 4 | 0 | 1 | 0 | 5 |
| Missing | 6 | 0 | 0 | 0 | 6 |
| Race/Ethnicity, Customized(Participants) | Cohort A: FGFR2 Rearrangements or Fusions | Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions | Cohort C: Negative for FGF/FGFR Alterations | Other | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 4 | 0 | 6 |
| Not Hispanic or Latino | 88 | 18 | 13 | 2 | 121 |
| Not Reported | 15 | 0 | 0 | 0 | 15 |
| Unknown | 1 | 0 | 0 | 0 | 1 |
| Captured as "Other" | 2 | 2 | 0 | 0 | 4 |
Showing the first 100 of 120 sites across 12 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Jan 2017 to primary completion in Feb 2022, 60 months.
Results were first posted in Feb 2023, 1 year after primary completion.
Of 173 phase 2 interventional studies under Cholangiocarcinoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 60 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemigatinib